Drug profile · INN
nicotine polacrilex
NICOTINE POLACRILEX
nicotine polacrilex (NICOTINE POLACRILEX) is a neuronal acetylcholine receptor; alpha4/beta2 agonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — nicotine polacrilex
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.89
Quick answer
nicotine polacrilex (NICOTINE POLACRILEX) is a neuronal acetylcholine receptor; alpha4/beta2 agonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Neuronal acetylcholine receptor; alpha4/beta2 agonist
Primary target: Neuronal acetylcholine receptor; alpha4/beta2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is nicotine polacrilex?
nicotine polacrilex (NICOTINE POLACRILEX) is a neuronal acetylcholine receptor; alpha4/beta2 agonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for nicotine polacrilex?
NICOTINE POLACRILEX is a marketed brand name for nicotine polacrilex. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nicotine polacrilex?
nicotine polacrilex has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.